- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 03.02. | The Platform Group - Feedback from January 2025 CMD | 284 | At The Platform Group's (TPG's) January 2025 capital markets day (CMD), management provided an overview of the headline FY24 results (above guidance) and updated future guidance released that day. TPG... ► Artikel lesen | ||
| 31.01. | Herantis (HEL: HRTIS) presents positive Phase Ib update | 199 | Herantis Pharma has announced an encouraging update from its ongoing Phase Ib trial for lead asset HER-096, which is being developed as a potential disease-modifying treatment for Parkinson's disease... ► Artikel lesen | ||
| 31.01. | IRLAB Therapeutics (STO: IRLAB-A) reports positive Phase I data for IRL757 in elderly cohort | 218 | IRLAB Therapeutics has reported positive top-line data from one of two ongoing Phase I studies evaluating the drug candidate IRL757 as a treatment for apathy. This study, financed by the McQuade Center... ► Artikel lesen | ||
| 31.01. | IRLAB (STO: IRLAB-A) reports positive Phase I data for IRL757 in elderly cohort | 229 | IRLAB Therapeutics has reported positive topline data from one of two ongoing Phase I studies, evaluating the drug candidate IRL757 as a treatment for apathy. This study, financed by the McQuade Center... ► Artikel lesen | ||
| 30.01. | OSE (PAR: OSE) launches AI immunotherapy partnership | 179 | OSE has signed a strategic partnership with Scienta Lab, aiming to model inflammatory diseases and identify predictive biomarkers of efficacy for immunotherapies. Scienta Lab is a France-based leader... ► Artikel lesen | ||
| 29.01. | Dowlais Group - American Axle & Manufacturing agreed offer | 1.455 | In 2024, Dowlais Group exited its loss-making Hydrogen business and announced a strategic review of Powder Metallurgy. The group has now announced an agreed offer from American Axle & Manufacturing... ► Artikel lesen | ||
| 29.01. | Biomea Fusion - An innovative approach to diabetes and obesity | 340 | Biomea Fusion is a clinical-stage biopharmaceutical company developing novel small molecules to cure metabolic diseases. Its proprietary FUSION System platform has created a pipeline of covalent candidates... ► Artikel lesen | ||
| 29.01. | Alkane Resources - Ventis secundis | 249 | Alkane's Q225 quarterly activities report demonstrated production of 14,852oz Au via the processing of 269kt ore (cf guidance of 260-290kt) at a head grade of 2.25g/t (2.1-2.3g/t) and 84.2% metallurgical... ► Artikel lesen | ||
| 28.01. | Foxtons Group - Market share gains in Sales continues apace | 231 | Foxtons Group's FY24 trading update confirmed revenue and adjusted operating profit growth of c 11% and c 33%, respectively, reflecting the developing success of the company's strategic vision. This... ► Artikel lesen | ||
| 28.01. | Information Services Corporation (ISC: TSX) - Management guidance for FY25 | 263 | Information Services Corporation (ISC: TSX) announced its management guidance for FY25, with revenue of C$257-267m and adjusted EBITDA of C$89m-97m (FY24 guidance: revenue of C$240m-250m, adjusted EBITDA... ► Artikel lesen | ||
| 28.01. | CQS Natural Resources Growth and Income - A natural resources specialist worth preserving | 228 | CQS Natural Resources Growth and Income (CYN) is a differentiated closed-end investment company seeking opportunities across small- and mid-cap mining and resource stocks, which in our view deserves... ► Artikel lesen | ||
| 28.01. | Information Services Corporation (ISV: TSX) - Management guidance for FY25 | 224 | Information Services Corporation (ISV: TSX) announced its management guidance for FY25, with revenue of C$257-267m and adjusted EBITDA of C$89m-97m (FY24 guidance: revenue of C$240m-250m, adjusted EBITDA... ► Artikel lesen | ||
| 28.01. | Invesco Asia Trust - A patient Asian champion | 196 | Invesco Asia Trust (IAT) delivered a 12.4% NAV total return (TR) over the 12 months to end-December 2024, bolstered by the stock market rally in China and Hong Kong (to which IAT's managers patiently... ► Artikel lesen | ||
| 28.01. | Lords Group Trading (LSE: LORD) - FY24 trading update points to positive outlook | 226 | As a result of a tough trading environment, Lords Group Trading expects FY24 revenue to be £436m (FY23: £463m) and EBITDA to be 'slightly' below expectations. The merchanting business was down 3.6%... ► Artikel lesen | ||
| 28.01. | Basilea Pharmaceutica (SIX: BSLN) banks another CHF2.2m milestone | 277 | Basilea Pharmaceutica has recorded another CHF2.2m in milestone payments triggered by both commercial anti-infective products, Cresemba and Zevtera, hitting sales thresholds in specific geographies... ► Artikel lesen | ||
| 28.01. | Basilea (SIX: BSLN) banks another CHF2.2m milestone | 404 | Basilea has recorded another CHF2.2m in milestone payments triggered by both commercial anti-infective products, Cresemba and Zevtera, hitting sales thresholds in specific geographies in 2024. This... ► Artikel lesen | ||
| 27.01. | Cordel Group - On the right tracks | 190 | Cordel's demonstrated solid H1 revenue growth to £2.3m (+16% y-o-y), with expanded gross margins and modest operating cost increases reducing losses. Recent contract momentum and a healthy pipeline... ► Artikel lesen | ||
| 24.01. | Care REIT - Q4 trading update and increased DPS target | 234 | In its Q424 trading update, Care REIT (Care), formerly Impact Healthcare REIT, announced an increased dividend target of 7.20p for 2025, a 3.6% increase on 2024, fully covered by adjusted 'cash earnings'.... ► Artikel lesen | ||
| 24.01. | Record PLC - Revenues are ahead of guidance | 211 | Record has published its trading update for the three months to 31 December 2024 (Q325). Increased volatility in currency markets has provided additional opportunities in value-add strategies and increased... ► Artikel lesen | ||
| 24.01. | Actinogen Medical - executive interview | 313 | Actinogen Medical is an ASX-listed Australian biotech developing its lead asset, emestedastat (Xanamem), a specific and selective 11ß-HSD1 inhibitor designed to prevent excess cortisol production in... ► Artikel lesen | ||
| 23.01. | Games Workshop Group - Core and licensing drive record H125 results | 409 | Games Workshop Group (GAW) has reported record interim results, yet again. The performance is impressive given the launch of the fourth edition of Age of Sigmar (AoS) in the period was up against a... ► Artikel lesen | ||
| 23.01. | Henderson International Income Trust - A HINT of better returns ahead | 210 | Henderson International Income Trust (HINT) has consistently met its income objective since inception, delivering dividend growth every year since 2011. However, a lag in relative performance in recent... ► Artikel lesen | ||
| 23.01. | Edinburgh Worldwide - Shareholders - your trust needs your vote | 287 | Edinburgh Worldwide Investment Trust (EWI) is under fire from activist US hedge fund Saba Capital. It is time for EWI's shareholders to make their feelings known following Saba's approach to seven UK... ► Artikel lesen | ||
| 23.01. | Oryzon Genomics (BME: ORY) doses first patient in new MDS trial | 103 | Oryzon Genomics has announced that the first patient has been dosed in its new Phase Ib trial in myelodysplastic syndrome (MDS), led by the Medical College of Wisconsin. This study (NCT06502145) aims... ► Artikel lesen | ||
| 23.01. | Fonix (AIM: FNX) announces special dividend | 82 | Fonix's H125 trading update confirmed that gross profit grew 6.5% to £9.8m and adjusted EBITDA grew 6.8% to £7.8m (53% of the consensus FY25 forecast). The company closed FY24 with underlying net cash... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
